New Risk • May 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$37.5m market cap). Reported Earnings • May 11
First quarter 2026 earnings: EPS in line with analyst expectations despite revenue beat First quarter 2026 results: EPS: US$0.013 (down from US$0.053 in 1Q 2025). Revenue: US$5.21m (up 6.9% from 1Q 2025). Net income: US$140.0k (down 75% from 1Q 2025). Profit margin: 2.7% (down from 11% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth. Aankondiging • May 02
Nephros, Inc. to Report Q1, 2026 Results on May 07, 2026 Nephros, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026 Valuation Update With 7 Day Price Move • Apr 28
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$3.32, the stock trades at a forward P/E ratio of 55x. Average forward P/E is 21x in the Machinery industry in the US. Total returns to shareholders of 134% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$6.38 per share. Aankondiging • Apr 01
Nephros Inc Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise Nephros, Inc. announced an expansion of its customer-facing, water-safety support capabilities following the ASSE 12080 Legionella Water Safety and Management Specialist Certification earned by Brianne McGuire, Director of Business Development. The certification strengthens Nephros’ ability to provide consultative support to healthcare facilities and other complex buildings seeking to reduce waterborne pathogen risk and adds specific proficiency in the development of effective Water Management Programs (WMPs). This new capability marks a meaningful extension of Nephros’ field support for customers seeking more robust water safety programs. In addition to point-of-use filtration solutions, product installations and replacements, as well as public education, Nephros can now provide a direct Water Management Program development service. Water Management Programs offer a structured framework for identifying water-quality risks, establishing control measures, assigning responsibility, and defining ongoing monitoring and response. The company believes this offering will create additional value for customers while opening a new avenue for revenue generation through chargeable consulting service. Nephros considers this support expansion to be differentiated by the depth of practical knowledge informing it. Besides the new ASSE 12080 certification, Ms. McGuire brings broad experience in technical concerns, waterborne risk, current guidance and standards, and industry best practices born out of direct engagement with healthcare facilities and other regulated environments. Her leadership of the Nephros Water Institute and other company public education initiatives has further expanded the company’s perspective on how complex water safety risks are understood and addressed in practice. As a result, Nephros believes it is well-positioned to apply a diverse scope of understanding to the design of WMPs informed by extensive practical expertise in risk, implementation and real-world operational challenges. Valuation Update With 7 Day Price Move • Mar 19
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to US$2.95, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 194% over the past three years. Reported Earnings • Mar 15
Full year 2025 earnings: EPS in line with analyst expectations despite revenue beat Full year 2025 results: EPS: US$0.11 (up from US$0.007 in FY 2024). Revenue: US$18.8m (up 33% from FY 2024). Net income: US$1.19m (up US$1.12m from FY 2024). Profit margin: 6.4% (up from 0.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.8% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth. Aankondiging • Mar 05
Nephros, Inc. to Report Q4, 2025 Results on Mar 12, 2026 Nephros, Inc. announced that they will report Q4, 2025 results After-Market on Mar 12, 2026 Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to US$3.87, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 23x in the Machinery industry in the US. Total returns to shareholders of 234% over the past three years. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$4.54, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 20x in the Machinery industry in the US. Total returns to shareholders of 269% over the past three years. Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to US$5.79, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 473% over the past three years. Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to US$4.42, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 344% over the past three years. Reported Earnings • Nov 09
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: EPS: US$0.032 (up from US$0.017 in 3Q 2024). Revenue: US$4.76m (up 35% from 3Q 2024). Net income: US$337.0k (up 84% from 3Q 2024). Profit margin: 7.1% (up from 5.2% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 63% per year, which means it is significantly lagging earnings growth. Aankondiging • Oct 31
Nephros, Inc. to Report Q3, 2025 Results on Nov 06, 2025 Nephros, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025 Valuation Update With 7 Day Price Move • Oct 28
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to US$5.74, the stock trades at a forward P/E ratio of 109x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 447% over the past three years. Aankondiging • Oct 09
Nephros, Inc. Launches New Pfas Filter for Point-Of-Use Protection of Potable Water Nephros, Inc. announced the launch of its new filter designed to reduce Total PFAS, or per- and polyfluoroalkyl substances (PFAS), in potable water. This product expands Nephros' portfolio to address a category of chemical contaminants that have drawn growing regulatory and public health attention. PFAS, sometimes referred to as "forever chemicals," are synthetic compounds found in a wide range of consumer and industrial products. They are notable for their persistence in the environment, as well as their bioaccumulative nature and risk to human health. Key Features of the Nephros 19-Series PFAS Filter: Independently tested to NSF Standards 42 and 53; Validated reduction of Total PFAS, including PFOA and PFOS; Effectively reduces other hazardous contaminants such as lead, asbestos, cysts, chlorine, taste, and odor; 3,145-gallon capacity with a 1.63 GPM flow rate; Provides long-term protection against persistent, health-threatening waterborne contaminants. Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to US$5.44, the stock trades at a forward P/E ratio of 104x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 467% over the past three years. New Risk • Aug 13
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 55% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 55% per year for the foreseeable future. Minor Risk Market cap is less than US$100m (US$45.2m market cap). New Risk • Aug 11
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 45% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 45% per year for the foreseeable future. Minor Risk Market cap is less than US$100m (US$41.3m market cap). Reported Earnings • Aug 10
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: EPS: US$0.022 (up from US$0.027 loss in 2Q 2024). Revenue: US$4.42m (up 36% from 2Q 2024). Net income: US$237.0k (up US$526.0k from 2Q 2024). Profit margin: 5.4% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 8.8% p.a. on average during the next 2 years, compared to a 4.7% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to US$3.00, the stock trades at a forward P/E ratio of 481x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 69% over the past three years. Aankondiging • Aug 01
Nephros, Inc. to Report Q2, 2025 Results on Aug 07, 2025 Nephros, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025 Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to US$5.00, the stock trades at a forward P/E ratio of 802x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 225% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$7.93 per share. Aankondiging • Jun 19
Nephros, Inc. Approves Election of Lisa Nettis as Director Nephros, Inc. announced at the AGM held on June 16, 2025, approved Lisa Nettis as director, to serve a three-year term expiring in 2028. Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to US$3.40, the stock trades at a forward P/E ratio of 545x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 89% over the past three years. New Risk • Jun 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 151% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$28.8m market cap). Valuation Update With 7 Day Price Move • May 22
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to US$2.63, the stock trades at a forward P/E ratio of 422x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 51% over the past three years. New Risk • May 13
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 151% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 151% per year for the foreseeable future. Minor Risk Market cap is less than US$100m (US$22.0m market cap). Reported Earnings • May 09
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: EPS: US$0.026 (up from US$0.016 loss in 1Q 2024). Revenue: US$4.88m (up 39% from 1Q 2024). Net income: US$558.0k (up US$727.0k from 1Q 2024). Profit margin: 11% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 33%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 9.3% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Aankondiging • May 01
Nephros, Inc., Annual General Meeting, Jun 16, 2025 Nephros, Inc., Annual General Meeting, Jun 16, 2025. Location: virtualshareholdermeeting.com/neph2025, United States Reported Earnings • Mar 07
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: US$0.007 (up from US$0.15 loss in FY 2023). Revenue: US$14.2m (flat on FY 2023). Net income: US$74.0k (up US$1.65m from FY 2023). Profit margin: 0.5% (up from net loss in FY 2023). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 9.1% p.a. on average during the next 2 years, compared to a 3.5% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. New Risk • Nov 26
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$2.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$2.2m free cash flow). Minor Risk Market cap is less than US$100m (US$16.2m market cap). Reported Earnings • Nov 10
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: US$0.017 (up from US$0.017 loss in 3Q 2023). Revenue: US$3.52m (down 6.0% from 3Q 2023). Net income: US$183.0k (up US$365.0k from 3Q 2023). Profit margin: 5.2% (up from net loss in 3Q 2023). The move to profitability was driven by lower expenses. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Aankondiging • Oct 31
Nephros, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nephros, Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024 Aankondiging • Oct 25
Nephros, Inc. Launches New HydraGuard 20" UltraFilter Nephros, Inc. announced the release of the HydraGuard 20" UltraFilter. This latest innovation enables the company to break into new markets and aid in compliance with water quality standards such as ANSI/AAMI ST108. The HydraGuard 20" model is an extension of the existing HydraGuard and designed to provide a higher-volume capacity and flow rate, while removing harmful contaminants like bacteria, viruses, and endotoxins. With this product, Nephros is poised to serve a broader range of customers, including companies within medical device manufacturing and pharmaceutical production, to ensure the highest level of water purity for industries that require strict quality standards. The HydraGuard 20" filter opens the door to expanded revenue opportunities and greater support for businesses and facilities struggling to establish or maintain compliance with strict regulatory standards. Most notably, the issuance of ANSI/AAMI ST 108 in late 2023 introduced new metrics for sterile processing, such as water testing schedules and parameters for bacteria and endotoxin presence. Solutions like the HydraGuard, along with other Nephros infection control products, provide exceptional retention of microbiological contaminants and support purification of water beyond the new standards. Regarding endotoxins specifically, Nephros in-line filters have the additional benefit of performance based on size exclusion, which achieves reliable and consistent retention compared to the more typical charged membranes. Major Estimate Revision • Aug 23
Consensus estimates of losses per share improve by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from US$13.6m to US$14.0m. EPS estimate increased from -US$0.09 per share to -US$0.08 per share. Machinery industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$4.75 unchanged from last update. Share price was steady at US$1.84 over the past week. Reported Earnings • Aug 11
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: US$0.027 loss per share (improved from US$0.042 loss in 2Q 2023). Revenue: US$3.25m (down 8.3% from 2Q 2023). Net loss: US$289.0k (loss narrowed 33% from 2Q 2023). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 100%. Revenue is forecast to grow 6.2% p.a. on average during the next 2 years, compared to a 3.2% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Aankondiging • Aug 01
Nephros, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Nephros, Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024 Recent Insider Transactions • May 17
President recently bought US$112k worth of stock On the 16th of May, Robert Banks bought around 50k shares on-market at roughly US$2.24 per share. This transaction increased Robert's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Robert has been a buyer over the last 12 months, purchasing a net total of US$152k worth in shares. Major Estimate Revision • May 16
Consensus EPS estimates upgraded to US$0.035 loss, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$16.7m to US$16.0m. 2024 losses expected to reduce from -US$0.065 to -US$0.035 per share. Consumer Durables industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$4.75 unchanged from last update. Share price rose 2.5% to US$2.27 over the past week. Reported Earnings • May 13
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2024 results: US$0.016 loss per share (improved from US$0.03 loss in 1Q 2023). Revenue: US$3.52m (down 4.7% from 1Q 2023). Net loss: US$169.0k (loss narrowed 45% from 1Q 2023). Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) exceeded analyst estimates by 50%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Consumer Durables industry in the US. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Breakeven Date Change • May 12
Forecast to breakeven in 2025 The analyst covering Nephros expects the company to break even for the first time. New forecast suggests losses will reduce by 68% to 2024. The company is expected to make a profit of US$538.0k in 2025. Average annual earnings growth of 121% is required to achieve expected profit on schedule. Aankondiging • Apr 14
Nephros, Inc., Annual General Meeting, May 23, 2024 Nephros, Inc., Annual General Meeting, May 23, 2024, at 10:00 US Eastern Standard Time. Location: 380 Lackawanna Place South Orange New Jersey United States Agenda: to Elect two directors to serve a three-year term expiring in 2027; Ratify the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; Approve the 2024 Equity Incentive Plan; Approve the compensation of the Company’s named executive officers on an advisory (non-binding) basis; and Act upon such other matters as may properly come before the meeting or any adjournment thereof. Reported Earnings • Mar 10
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: US$0.15 loss per share (improved from US$0.44 loss in FY 2022). Revenue: US$14.2m (up 43% from FY 2022). Net loss: US$1.58m (loss narrowed 65% from FY 2022). Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) also missed analyst estimates by 30%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Consumer Durables industry in the US. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. New Risk • Mar 08
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$1.7m Forecast net loss in 1 year: US$677k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$677k net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (US$31.8m market cap). Aankondiging • Mar 01
Nephros, Inc. to Report Q4, 2023 Results on Mar 07, 2024 Nephros, Inc. announced that they will report Q4, 2023 results After-Market on Mar 07, 2024 Buy Or Sell Opportunity • Feb 05
Now 21% undervalued Over the last 90 days, the stock has risen 100% to US$3.60. The fair value is estimated to be US$4.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 22% in a year. Earnings are forecast to grow by 60% in the next year. Buying Opportunity • Dec 28
Now 25% undervalued Over the last 90 days, the stock is up 136%. The fair value is estimated to be US$4.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 22% in a year. Earnings is forecast to grow by 60% in the next year. Major Estimate Revision • Nov 21
Consensus EPS estimates upgraded to US$0.12 loss The consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -US$0.13 to -US$0.115 per share. Revenue forecast steady at US$14.8m. Consumer Durables industry in the US expected to see average net income decline 3.8% next year. Consensus price target of US$4.50 unchanged from last update. Share price was steady at US$2.10 over the past week. Major Estimate Revision • Nov 15
Consensus estimates of losses per share improve by 30% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from US$14.1m to US$14.8m. EPS estimate increased from -US$0.185 per share to -US$0.13 per share. Consumer Durables industry in the US expected to see average net income decline 3.7% next year. Consensus price target up from US$3.00 to US$4.50. Share price rose 16% to US$2.09 over the past week. Breakeven Date Change • Nov 10
Forecast to breakeven in 2025 The analyst covering Nephros expects the company to break even for the first time. New forecast suggests losses will reduce by 67% per year to 2024. The company is expected to make a profit of US$649.0k in 2025. Average annual earnings growth of 96% is required to achieve expected profit on schedule. Aankondiging • Nov 03
Nephros, Inc., Hires Judy Krandel as Chief Financial Officer Nephros, Inc. announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the companys finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephross long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, investment, operations, financial reporting and oversight, as well as formal accounting expertise Prior to joining Nephros, Ms. Krandel served as the Chief Financial Officer of Recruiter.com, where she worked closely with the CEO to leverage AI and new technology to drive company growth while also building public market capitalization and enterprise value. Additionally, Ms. Krandel was responsible for developing strategies for capital allocation, internal growth, and M&A while at Paltalk, Inc. Ms. Krandel holds a Bachelor of Science in Finance from the Wharton School and a Master of Business Administration from the University of Chicago Booth School of Business. In addition to previous roles as Chief Financial Officer for two other publicly traded companies, Ms. Krandel has been simultaneously active in multiple corporate and advisory boards.. Aankondiging • Oct 26
Nephros, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Nephros, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023 New Risk • Oct 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$1.2m net loss next year). Share price has been volatile over the past 3 months (9.8% average weekly change). Market cap is less than US$100m (US$19.4m market cap). New Risk • Aug 10
New major risk - Revenue and earnings growth Earnings have declined by 7.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 7.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (US$15.8m market cap). Aankondiging • Jul 28
Nephros, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Nephros, Inc. announced that they will report Q2, 2023 results After-Market on Aug 09, 2023 New Risk • Jun 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$1.4m net loss next year). Market cap is less than US$100m (US$19.4m market cap). Breakeven Date Change • May 12
No longer forecast to breakeven The analyst covering Nephros no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of US$41.0k in 2024. New forecast suggests the company will make a loss of US$121.0k in 2024. Reported Earnings • May 11
First quarter 2023 earnings: EPS misses analyst expectations First quarter 2023 results: US$0.03 loss per share (improved from US$0.20 loss in 1Q 2022). Revenue: US$3.70m (up 69% from 1Q 2022). Net loss: US$306.0k (loss narrowed 85% from 1Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 50%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 2.4% growth forecast for the Consumer Durables industry in the US. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Breakeven Date Change • Apr 06
Forecast to breakeven in 2024 The 2 analysts covering Nephros expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 55% to 2023. The company is expected to make a profit of US$41.0k in 2024. Average annual earnings growth of 105% is required to achieve expected profit on schedule. Major Estimate Revision • Mar 15
Consensus EPS estimates fall by 37% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$12.8m to US$11.5m. Losses expected to increase from US$0.15 per share to US$0.20. Consumer Durables industry in the US expected to see average net income decline 33% next year. Consensus price target of US$3.00 unchanged from last update. Share price fell 8.8% to US$1.03 over the past week. Reported Earnings • Mar 10
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: US$0.44 loss per share (further deteriorated from US$0.41 loss in FY 2021). Revenue: US$9.98m (down 4.1% from FY 2021). Net loss: US$4.55m (loss widened 11% from FY 2021). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 5.0%. Revenue is forecast to grow 22% p.a. on average during the next 2 years, while revenues in the Consumer Durables industry in the US are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings. Price Target Changed • Feb 15
Price target decreased by 27% to US$3.00 Down from US$4.13, the current price target is provided by 1 analyst. New target price is 150% above last closing price of US$1.20. Stock is down 75% over the past year. The company is forecast to post a net loss per share of US$0.69 next year compared to a net loss per share of US$0.41 last year. Board Change • Feb 15
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Alisa Lask was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Feb 04
Nephros, Inc. Announces Board Changes On January 30, 2023, Thomas Gwydir resigned from the board of directors of Nephros, Inc., effective February 1, 2023. On February 2, 2023, the company’s board of directors appointed Alisa Lask to serve as a member of its Audit Committee, filling the vacancy created by Mr. Gwydir’s resignation. Aankondiging • Nov 16
Nephros, Inc. announced delayed 10-Q filing On 11/15/2022, Nephros, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Price Target Changed • Nov 16
Price target decreased to US$3.63 Down from US$4.13, the current price target is an average from 2 analysts. New target price is 241% above last closing price of US$1.06. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$0.63 next year compared to a net loss per share of US$0.41 last year. Major Estimate Revision • Nov 09
Consensus EPS estimates fall by 23% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$10.5m to US$10.3m. Losses expected to increase from US$0.51 per share to US$0.63. Consumer Durables industry in the US expected to see average net income decline 15% next year. Consensus price target of US$3.63 unchanged from last update. Share price was steady at US$1.04 over the past week. Reported Earnings • Nov 04
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: US$0.13 loss per share (further deteriorated from US$0.12 loss in 3Q 2021). Revenue: US$2.41m (down 8.6% from 3Q 2021). Net loss: US$1.33m (loss widened 8.6% from 3Q 2021). Revenue missed analyst estimates by 4.5%. Earnings per share (EPS) also missed analyst estimates by 182%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, while revenues in the Consumer Durables industry in the US are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings. Aankondiging • Sep 10
Nephros Appoints Joe Harris to Its Board of Directors Nephros, Inc. announced the appointment of Joe Harris to its Board of Directors. Joe Harris is currently the Midwest, Sales Director at Murj. Previous positions have included East, Areas Sales Director at HeartFlow, Inc., Midwest Regional Sales Director at BIOTRONIK, and Regional Sales Manager at Boston Scientific. Joe is also a U.S. Army veteran. He received his B.S. in Systems Engineering Economics from the United States Military Academy at West Point, and his MBA in Marketing Finance from the University of Michigan. Aankondiging • Aug 24
Wes Lobo, Chief Commercial Officer of Nephros, Inc. Resigns, to Be Effective No Later Than September 30, 2022 On August 17, 2022, Wes Lobo, Chief Commercial Officer of Nephros, Inc. notified the Company that he is resigning his employment with the Company, to be effective no later than September 30, 2022. 
